The
Cleveland HeartLab is taking its life-saving technology to heart. A real heart, that is.
The company � affiliated with the
Cleveland Clinic � has developed a profile of tests focused on managing and reducing inflammation, a root cause of heart disease.
Using an enzyme immunoassay (a biochemical technique used to detect the presence of an antibody in a sample), CHL uses its CardioMPO technology to test for myeloperoxidase in human plasma.
The product received its FDA approval in May of 2005 for use on the market. Cleveland HeartLab purchased that technology in Nov. 2009 from Cleveland-based PrognostiX.
Cleveland HeartLab, located on the campus of the Cleveland Clinic, bills itself as a specialty clinical laboratory and disease management company focused on novel molecular biomarker technologies and the creation of proprietary diagnostic tests.
But the company doesn't stop there. CHL also runs a research and development laboratory where next-generation cardiovascular disease biomarkers are being developed for use in the clinical community.
CHL has a significant pipeline of tests protected by exclusive intellectual property and target large, under-addressed markets. In addition, an agreement with the Cleveland Clinic provides the company access to intellectual property developed at the Clinic in the areas of cardiovascular and inflammatory biomarkers.
The company is keeping itself busy. In August 2010, the HeartLab hosted the summer symposium "Where Inflammation Meets Lipids," with doctors attending from all over the world.
"Things are going great," says CHL spokeswoman Rachele Rhea. "We are super swamped right now."
Source: Rachele Rhea, Cleveland HeartLab Writer: Colin McEwen